Pfizer said interim data on its coronavirus disease 2019 (COVID-19) vaccine show 90% efficacy; meanwhile, President-elect Joe Biden released the names of his coronavirus advisory board.
Pfizer said Monday that its coronavirus disease 2019 (COVID-19) vaccine appears to be 90% effective, putting it closer to apply to the FDA for an emergency use authorization.
Also on Monday, the transition team for President-elect Joe Biden and Vice President–elect Kamala Harris released the names of scientific, medical, and public health professionals who will serve on its Transition COVID-19 Advisory Board.
The board will be led by cochairs David Kessler, MD; Vivek Murthy, MD, MBA; and Marcella Nunez-Smith, MD, MHS. Kessler, who served as FDA commissioner from 1990 to 1997 during both Republican and Democratic administrations, is a professor of pediatrics and epidemiology and biostatistics at the University of California, San Francisco (UCSF). Murthy was the surgeon general from 2014 to 2017 under President Barack Obama, and Nunez-Smith is an associate professor of internal medicine, public health, and management at Yale University and the associate dean for health equity research at the Yale School of Medicine.
Both announcements come less than 48 hours after the race was called for Biden by the Associated Press and all news networks (with independent vote monitors) after incumbent President Donald Trump failed to reach the 270 Electoral College vote threshold.
Worldwide, COVID-19 has killed more than 1.2 million people and more than 230,000 in the United States.
The Pfizer announcement doesn’t mean a vaccine is imminent. “More data on safety is also needed, and we are continuing to accumulate that safety data as part of our ongoing clinical study,” said CEO Albert Bourla said in a statement. He said that a median of 2 months of those data after the second and final dose of the vaccine will be available by the third week of November.
Authorities have stressed it’s unlikely any vaccine will be available before the end of the year, and initial supplies are expected to go to health care workers and vulnerable populations.
Speaking on Sunday’s “Face the Nation,” former FDA Commissioner Scott Gottlieb, MD, predicted that Biden would be taking office at the “apex” of the pandemic and then it would hopefully start to decline, but said the virus would not be conquered in 2021.
“And the only question is going to be how many people have died in the course of this and how many people have been infected. And we have to keep those numbers down as much as possible," he said.
Transition COVID-19 Advisory Board Meets
Biden spoke Monday after meeting with the advisory board and said his administration “will follow the science” in fighting the virus.
He said, however, that production and capacity for any vaccine would take months and urged the public to wear a mask.
The other members of the advisory board are:
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More